Which of the following statements is accurate regarding anti-inflammatory drugs that are cyclooxygenase-2 (COX-2) selective?

Choice A rationale Celecoxib is a highly selective inhibitor of the COX-2 enzyme, which is primarily induced at sites of inflammation and mediates the synthesis of pro-inflammatory prostaglandins. By specifically blocking COX-2, Celecoxib aims to reduce inflammation and pain with a lower risk of gastrointestinal adverse effects compared to non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) that also inhibit constitutive COX-1. Choice B rationale COX-2 selective inhibitors, such as celecoxib, are considered second-generation NSAIDs, developed after the initial non-selective NSAIDs (like aspirin, ibuprofen), which are classified as first-generation. This newer class was designed to minimize the adverse effects, particularly gastrointestinal, associated with the non-selective inhibition of the constitutive COX-1 enzyme. Choice C rationale The primary advantage and design feature of COX-2 selective inhibitors are their reduced risk of gastrointestinal adverse effects, including peptic ulcers, compared to non-selective NSAIDs. Non-selective NSAIDs inhibit COX-1, which produces protective prostaglandins necessary for maintaining the gastric mucosal barrier, making their inhibition the main cause of ulcers. Choice D rationale COX-2 selective inhibitors work by reducing inflammation. The COX-2 enzyme catalyzes the conversion of arachidonic acid into pro-inflammatory prostaglandins. By inhibiting this enzyme, these drugs decrease the synthesis of these inflammatory mediators, thereby lessening the signs and symptoms of inflammation, pain, and fever.